Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHILD: Autologous Cardiac Stem Cell Injection in HLHS
NCT03406884Phase 1Completed
- Start
- Oct 2019
- Primary completion
- Jul 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of autologous c-kit+ cardiac stem cells in hypoplastic left heart syndrome (HLHS) (3 arms). Primary endpoints: Incidence of Treatment Related Major Adverse Cardiac Events at 30 days, Number of C-kit+ Products at Day 1 and 5 more. Started Oct 2019; status: completed.
02
Drugs
autologous c-kit+ cardiac stem cells
03
Conditions
hypoplastic left heart syndrome (HLHS)
Beyond the preview
Go deeper on NCT03406884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03406884.